Avastin Hearing's Deadline For Written Submissions Is Indefinitely Delayed

Presiding Officer Karen Midthun postpones the submission deadline for written summaries of arguments by Genentech and CDER until one week after the formal hearing notice is issued, although it remains unclear when that will occur.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet